Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of exosome mediated RNA CASC15 in intervention of synaptic loss of Alzheimer's disease

A technology for Alzheimer's disease and exosomes, applied in the field of biomedicine, can solve problems such as unknown effects, and achieve the effect of improved synaptic structure and good biocompatibility

Pending Publication Date: 2022-07-12
AIR FORCE MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, basic research is developing a targeted vaccine against the key pathogenic protein molecules of AD, but the final effect is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of exosome mediated RNA CASC15 in intervention of synaptic loss of Alzheimer's disease
  • Application of exosome mediated RNA CASC15 in intervention of synaptic loss of Alzheimer's disease
  • Application of exosome mediated RNA CASC15 in intervention of synaptic loss of Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The present invention will be described in further detail below with reference to the embodiments, which are to explain rather than limit the present invention.

[0022] 1. Low expression of CASC15 is significantly correlated with the occurrence of AD

[0023] The gene sequence of long non-coding RNA CASC15 is as follows:

[0024] CASC15 (human): Chromosome6-NC_000006.12

[0025] The gene sequence of 2610307P16Rik (mouse origin) is as follows: Chromosome13-NC_000079.7

[0026] We performed hcluster hierarchical clustering of more than 200 clinical AD samples by bioinformatics methods.

[0027] According to the present invention, through GWAS analysis, it is found that multiple SNP sites in the CASC15 gene are closely related to the risk of AD. Further, more than 200 clinical AD samples were subjected to hcluster hierarchical clustering by bioinformatics methods, among which the postmortem brain tissue of AD patients was detected by RNA-Seq, and the chip data was obta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of exosome mediated RNA CASC15 in intervention of Alzheimer's disease synaptic loss, analysis finds that CASC15 low expression is significantly related to AD occurrence, then the exosome of overload CASC15 is separated and purified through an ultra-high speed centrifugation technology, and the treatment effect of the exosome is verified in mice with early Alzheimer's disease. The synaptic loss is one of the earliest symbolic events of the Alzheimer's disease, exosome-mediated 2610307P16Rik (mouse source) transmission can be effectively enriched in the cerebral cortex and hippocampal tissue of a mouse, the synaptic structure of neurons in the hippocampal CA1 region of the mouse is remarkably improved, and the early Alzheimer's disease is cured.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to the application of exosome-mediated RNA CASC15 to interfere with Alzheimer's disease synapse loss. Background technique [0002] Alzheimer's disease (AD) has a slow course of disease, and the early clinical manifestations are simple memory impairment. Synaptic loss is one of the earliest hallmark events of AD. Synapse loss showed the most significant correlation with cognitive decline. [0003] Due to the complex pathological causes and unclear pathogenic factors of AD, very few successful drugs have been developed for AD patients, and the drugs have poor efficacy and cannot block the pathogenesis of AD. Currently, the FDA-approved drugs for the treatment of AD include Tacrine, Donepezil, Rivastigmine, Galanthamine, Memantine and the newly announced drug Aducanumab for the treatment of mild to moderate AD. Even Aducanumab, the newly approved drug for the treatment of mild to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883A61K31/7088A61K47/46A61P25/28A01K67/027
CPCC12Q1/6883A61K31/7088A61K47/46A61P25/28A01K67/0278C12Q2600/136C12Q2600/158C12Q2600/178A01K2207/15A01K2217/072A01K2227/105A01K2267/0312
Inventor 邹远康王磊骆文静张建彬张克英官瑞丽孙亚菲翟茂登
Owner AIR FORCE MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com